Baynes Roy D.
SEC CIK 1680739 · EDGAR
BoughtSold
Most active insiders at NTRA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Rabinowitz Matthew | EXECUTIVE COB, Dir | — | $124.05M |
| 2 | Chapman Steven Leonard | CEO AND Pres, Dir | — | $93.95M |
| 3 | BOTHA ROELOF | Dir | — | $34.89M |
| 4 | RABINOWITZ DANIEL | SEC. AND CLO | — | $23.83M |
| 5 | Moshkevich Solomon | Pres, CLINICALDIAGNOSTICS | — | $22.88M |
| 6 | Sheena Jonathan | Dir, CO-FOUNDER | — | $22.83M |
| 7 | Brophy Michael Burkes | CFO | — | $22.14M |
| 8 | ROSENMAN HERM | Dir | — | $15.14M |
| 9 | Fesko John | Pres, CHIEF BUS. Off | — | $9.35M |
| 10 | Baynes Roy D. | Dir | — | $2.81M |
Transactions 46
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-06-30 20:05 | 2026-06-26 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | A - Grant | — | +1,646 | 20.2K | +9% | — |
| DT | 2026-06-16 16:42 | 2026-06-12 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Dir | M - OptEx | $21.38 | +4,500 | 46.0K | +11% | +$96.2K |
| DT | 2026-06-16 16:42 | 2026-06-12 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Dir | S - Sale+OE | $50.00 | -4,500 | 41.5K | -10% | -$225.0K |
| D | 2026-05-21 17:00 | 2026-05-19 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Dir | A - Grant | $0.00 | +4,000 | 41.5K | +11% | $0 |
| DT | 2026-05-06 20:00 | 2026-05-05 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Dir | M - OptEx | $18.27 | +4,500 | 42.0K | +12% | +$82.2K |
| DT | 2026-05-06 20:00 | 2026-05-05 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Dir | S - Sale+OE | $46.65 | -4,500 | 37.5K | -11% | -$209.9K |
| DT | 2026-05-04 16:27 | 2026-05-01 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Dir | M - OptEx | $6.82 | +9,750 | 47.2K | +26% | +$66.5K |
| DT | 2026-05-04 16:27 | 2026-05-01 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Dir | S - Sale+OE | $44.22 | -9,750 | 37.5K | -21% | -$431.1K |
| 2026-04-28 20:35 | 2026-04-24 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | A - Grant | — | +83 | 18.5K | +0.5% | — | |
| DMT | 2026-04-16 16:05 | 2026-04-14 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Dir | M - OptEx | $17.60 | +32.8K | 70.2K | +87% | +$576.3K |
| DMT | 2026-04-16 16:05 | 2026-04-14 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Dir | S - Sale+OE | $41.29 | -32.8K | 37.5K | -47% | -$1.35M |
| DT | 2026-04-07 18:17 | 2026-04-06 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Dir | M - OptEx | $26.52 | +10.0K | 47.5K | +27% | +$265.2K |
| DT | 2026-04-07 18:17 | 2026-04-06 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Dir | S - Sale+OE | $33.00 | -10.0K | 37.5K | -21% | -$330.0K |
| 2026-02-03 | 2026-01-30 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | A - Grant | — | +70 | 18.4K | +0.4% | — | |
| DM | 2025-11-21 | 2025-11-19+ | NTRA | Natera, Inc. | Baynes Roy D. | Dir | S - Sale+OE | $219.85 | -12.8K | 24.8K | -34% | -$2.81M |
| DM | 2025-11-21 | 2025-11-19+ | NTRA | Natera, Inc. | Baynes Roy D. | Dir | M - OptEx | $41.07 | +12.8K | 19.0K | +207% | +$524.9K |
| 2025-11-04 | 2025-10-31 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | A - Grant | — | +93 | 18.4K | +0.5% | — | |
| 2025-07-29 | 2025-07-25 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | A - Grant | — | +108 | 18.3K | +0.6% | — | |
| 2025-07-01 | 2025-06-27 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | A - Grant | — | +2,143 | 18.2K | +13% | — | |
| D | 2025-05-16 | 2025-05-15 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Dir | A - Grant | $0.00 | +6,500 | 37.5K | +21% | $0 |
| 2025-04-29 | 2025-04-25 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | A - Grant | — | +116 | 16.0K | +0.7% | — | |
| D | 2025-02-10 | 2025-02-06 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Dir | M - OptEx | $17.44 | +10.0K | 41.0K | +32% | +$174.4K |
| D | 2025-02-10 | 2025-02-06 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Dir | S - Sale+OE | $22.00 | -10.0K | 31.0K | -24% | -$220.0K |
| 2025-02-04 | 2025-01-31 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | A - Grant | — | +92 | 15.9K | +0.6% | — | |
| D | 2025-01-23 | 2025-01-23 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Dir | M - OptEx | $17.50 | +16.0K | 47.0K | +52% | +$280.0K |
| D | 2025-01-23 | 2025-01-23 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Dir | S - Sale+OE | $20.00 | -16.0K | 31.0K | -34% | -$320.0K |
| DM | 2024-11-15 | 2024-11-15 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | S - Sale+OE | $146.11 | -37.2K | 47.5K | -44% | -$5.44M |
| DM | 2024-11-15 | 2024-11-15 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | M - OptEx | $23.48 | +37.2K | 53.0K | +236% | +$874.2K |
| 2024-10-29 | 2024-10-25 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | A - Grant | — | +124 | 15.8K | +0.8% | — | |
| 2024-07-30 | 2024-07-26 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | A - Grant | — | +143 | 15.7K | +0.9% | — | |
| 2024-07-02 | 2024-06-28 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | A - Grant | — | +2,964 | 15.5K | +24% | — | |
| D | 2024-05-10 | 2024-05-08 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Dir | A - Grant | $0.00 | +6,500 | 31.0K | +27% | $0 |
| 2024-04-30 | 2024-04-26 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | A - Grant | — | +169 | 12.6K | +1% | — | |
| 2024-01-30 | 2024-01-26 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | A - Grant | $63.79 | +215 | 12.4K | +2% | +$13.7K | |
| 2023-10-31 | 2023-10-27 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | A - Grant | $42.60 | +322 | 12.2K | +3% | +$13.7K | |
| 2023-08-01 | 2023-07-28 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | A - Grant | $48.48 | +264 | 11.9K | +2% | +$12.8K | |
| D | 2023-07-05 | 2023-06-30 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | A - Grant | — | +2,750 | 11.6K | +31% | — |
| D | 2023-05-26 | 2023-05-25 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | M - OptEx | — | +3,534 | 8,856 | +66% | — |
| D | 2023-05-19 | 2023-05-17 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Dir | A - Grant | $0.00 | +4,500 | 24.5K | +22% | $0 |
| 2023-04-18 | 2023-04-14 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | A - Grant | $54.73 | +228 | 5,322 | +4% | +$12.5K | |
| 2023-01-18 | 2023-01-13 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | A - Grant | $40.01 | +312 | 5,094 | +7% | +$12.5K | |
| 2022-10-18 | 2022-10-14 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | A - Grant | $45.42 | +275 | 4,782 | +6% | +$12.5K | |
| A | 2022-09-02 | 2022-07-08 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | A - Grant | $0.00 | +344 | 4,507 | +8% | $0 |
| D | 2022-06-27 | 2022-06-23 | ATRA | Atara Biotherapeutics, Inc. | Baynes Roy D. | Dir | A - Grant | $0.00 | +20.5K | 43.5K | +89% | $0 |
| D | 2022-05-27 | 2022-05-25 | NTRA | Natera, Inc. | Baynes Roy D. | Dir | M - OptEx | — | +1,307 | 4,163 | +46% | — |
| D | 2022-05-12 | 2022-05-11 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Dir | A - Grant | $0.00 | +3,000 | 20.0K | +18% | $0 |
Purchase Sale Sale after option exercise All abbreviations